Cooper Financial Group Purchases 156 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Cooper Financial Group grew its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 3.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 4,334 shares of the specialty pharmaceutical company’s stock after acquiring an additional 156 shares during the period. Cooper Financial Group’s holdings in Jazz Pharmaceuticals were worth $534,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. CWA Asset Management Group LLC purchased a new stake in Jazz Pharmaceuticals in the third quarter worth $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after buying an additional 100,112 shares in the last quarter. Centre Asset Management LLC purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth about $9,335,000. Pacer Advisors Inc. increased its stake in shares of Jazz Pharmaceuticals by 15.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after acquiring an additional 278,465 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after acquiring an additional 48,708 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Up 1.4 %

JAZZ opened at $123.16 on Tuesday. The stock has a market capitalization of $7.45 billion, a price-to-earnings ratio of 17.35, a PEG ratio of 1.04 and a beta of 0.56. The firm has a 50 day moving average price of $122.29 and a 200-day moving average price of $114.27. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Analyst Ratings Changes

A number of equities research analysts have weighed in on JAZZ shares. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Robert W. Baird raised their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. TD Cowen dropped their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $177.00.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,253 shares of company stock valued at $1,001,434. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.